Professor Victoria Werth and Doctor Guillermo J. Pons-Estel highlights the new treatment safety and efficacy and impact of mental health outcomes in SLE. This podcast discusses efficacy and safety of SC anifrolumab in SLE, and the associations between discrimination and PROs and the role of mental health in these associations among a multiracial, multiethnic cohort with SLE. If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/

Professor Ed Vital discusses two key publications covered on the Lupus Forum in December. his podcast reviews data from a randomised, double-blind, placebo-controlled Phase Ib/IIa trial of the anti-CD38 monoclonal antibody CM313 in adults with systemic lupus erythematosus (SLE), focusing on safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy. The episode also examines predictors of damage accrual by organ domain in SLE, highlighting factors associated with long-term disease outcomes. If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/

Professor Richard Furie and Doctor Guillermo J. Pons-Estel review two key publications covered on the Lupus Forum in November. This podcast reports data from a multicentre, randomised, double-blind, placebo-controlled trial evaluating low-dose belimumab in patients with systemic lupus erythematosus (SLE), with a focus on disease flare prevention. The episode also reports findings on the efficacy and safety of allogeneic CD19 CAR NK-cell therapy in SLE, based on a case series conducted in China in patients with mild disease activity. If you are interested in the papers discussed, head on over to the Lupus Forum today!

Professor Vibeke Strand highlights the emerging treatments in SLE and LN. This podcast reports the efficacy and safety results of a Phase 3 trial of telitacicept at a dose of 160mg weekly as compared with PBO in Chinese persons with active SLE. The efficacy and safety of SC secukinumab 300mg compared with PBO, in combination with the SoC, in patients with active LN is also reported.

If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly podcasts, all through this free independent resource: https://lupus-forum.com/

Join Professor Ed Vital, Dr Guillermo J. Pons-Estel, Professor Richard Furie and Professor Chris Edwards on the Lupus Forum for their discussion of the recent webinar “Early use of advanced therapies in lupus”. Watch them discuss key highlights from the webinar, including limitations of SoC, insights from clinical trials and strategies for early intervention with advanced therapies.

Visit www.lupusforum.com to access the full webinar content, including detailed slide materials from Dr Guillermo J. Pons-Estel, Professor Richard Furie and Professor Chris Edwards.

Join Professors Ed Vital and Maria Dall'Era as they review their highlights of the recent ACR 2025 congress, watch them discuss their abstracts and highlight key information.

Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 4 of ACR 2025 (Wednesday, October 29th).

Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 3 of ACR 2025 (Tuesday, October 28th).

Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 2 of ACR 2025 (Monday, October 27th).

Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 1 of ACR 2025 (Sunday, October 26th).